{"fetched":"2026-10-19","previousFetched":"2026-10-12","keepDays":90,"changes":[{"detected":"2026-10-19","drugId":"f-18-fdg-brain","nct":"NCT04665739","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2032-09-01","kind":"primary-completion","from":"2027-07-01","to":"2032-09-01"},{"detected":"2026-10-19","drugId":"fluciclovine-f18","nct":"NCT04787744","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","phases":["PHASE2","PHASE3"],"sponsor":"VA Office of Research and Development","primaryCompletion":"2026-10-02","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-19","drugId":"fluciclovine-f18","nct":"NCT04787744","title":"Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer","phases":["PHASE2","PHASE3"],"sponsor":"VA Office of Research and Development","primaryCompletion":"2026-10-02","kind":"primary-completion","from":"2026-09-30","to":"2026-10-02"},{"detected":"2026-10-19","drugId":"itm-11","nct":"NCT05691465","title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2027-06-01","kind":"primary-completion","from":"2026-11-02","to":"2027-06-01"},{"detected":"2026-10-19","drugId":"f-18-flutemetamol","nct":"NCT07873463","title":"Flutemetamol F 18 Injection Formulation Comparison","phases":["PHASE2"],"sponsor":"GE Healthcare","primaryCompletion":"2027-02-25","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-19","drugId":"radioactive-iodine","nct":"NCT07874321","title":"MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid Cancer","phases":["PHASE2"],"sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","primaryCompletion":"2027-12-31","kind":"new-study","to":"RECRUITING"},{"detected":"2026-10-12","drugId":"f-18-fdg-brain","nct":"NCT01542879","title":"Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Stanford University","primaryCompletion":"2022-08-08","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-10-12","drugId":"f-18-fdg-brain","nct":"NCT01542879","title":"Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Stanford University","primaryCompletion":"2022-08-08","kind":"results-posted"},{"detected":"2026-10-12","drugId":"f-18-fdg-brain","nct":"NCT01542879","title":"Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer","phases":["PHASE1","PHASE2"],"sponsor":"Stanford University","primaryCompletion":"2022-08-08","kind":"primary-completion","from":"2025-10","to":"2022-08-08"},{"detected":"2026-10-12","drugId":"f-18-fdg-brain","nct":"NCT02824419","title":"Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis","phases":["PHASE2","PHASE3"],"sponsor":"Turku University Hospital","primaryCompletion":"2017-02","kind":"status","from":"UNKNOWN","to":"TERMINATED"},{"detected":"2026-10-12","drugId":"f-18-fdg-brain","nct":"NCT02824419","title":"Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis","phases":["PHASE2","PHASE3"],"sponsor":"Turku University Hospital","primaryCompletion":"2017-02","kind":"primary-completion","from":"2017-05","to":"2017-02"},{"detected":"2026-10-12","drugId":"durvalumab","nct":"NCT03916419","title":"Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"Washington University School of Medicine","primaryCompletion":"2025-09-28","kind":"results-posted"},{"detected":"2026-10-12","drugId":"radium-223","nct":"NCT04071236","title":"Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy","phases":["PHASE1","PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2027-04-30","kind":"status","from":"SUSPENDED","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-12","drugId":"cabozantinib","nct":"NCT05663710","title":"Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC","phases":["PHASE1","PHASE2"],"sponsor":"M.D. Anderson Cancer Center","primaryCompletion":"2027-10-30","kind":"status","from":"RECRUITING","to":"SUSPENDED"},{"detected":"2026-10-12","drugId":"cabozantinib","nct":"NCT05836571","title":"Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma","phases":["PHASE2"],"sponsor":"National Cancer Institute LAO","primaryCompletion":"2028-05-15","kind":"primary-completion","from":"2026-05-15","to":"2028-05-15"},{"detected":"2026-10-12","drugId":"pluvicto","nct":"NCT07860554","title":"Pluvicto for the Treatment of African American Men With Metastatic Castration-Resistant Prostate Cancer","phases":["PHASE2"],"sponsor":"Emory University","primaryCompletion":"2027-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-12","drugId":"ga-68-fapi-46","nct":"NCT07861217","title":"Paediatric Sarcoma, Hybrid Imaging & FAPI - Raising the Diagnostic Standard for Paediatric Sarcoma Patients, Combining Novel Radiotracer FAPI and Whole-body PET/MRI","phases":["PHASE2"],"sponsor":"Copenhagen University Hospital, Rigshospitalet","primaryCompletion":"2028-12","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-10-05","drugId":"lutathera","nct":"NCT02236910","title":"An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours","phases":["PHASE2"],"sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","primaryCompletion":"2027-12","kind":"status","from":"UNKNOWN","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"lutathera","nct":"NCT02236910","title":"An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours","phases":["PHASE2"],"sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","primaryCompletion":"2027-12","kind":"primary-completion","from":"2025-12","to":"2027-12"},{"detected":"2026-10-05","drugId":"sunitinib","nct":"NCT02465060","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2027-12-31","kind":"primary-completion","from":"2026-12-31","to":"2027-12-31"},{"detected":"2026-10-05","drugId":"lutathera","nct":"NCT03454763","title":"Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors","phases":["PHASE2"],"sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","primaryCompletion":"2025-01","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"rituximab","nct":"NCT03719131","title":"Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy","phases":["PHASE2"],"sponsor":"Emory University","primaryCompletion":"2022-09-27","kind":"status","from":"ACTIVE_NOT_RECRUITING","to":"COMPLETED"},{"detected":"2026-10-05","drugId":"radium-223","nct":"NCT04071223","title":"Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2026-07-27","kind":"primary-completion","from":"2026-10-01","to":"2026-07-27"},{"detected":"2026-10-05","drugId":"cabozantinib","nct":"NCT04310007","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2027-03-31","kind":"primary-completion","from":"2026-12-31","to":"2027-03-31"},{"detected":"2026-10-05","drugId":"pylarify","nct":"NCT04573231","title":"Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer","phases":["PHASE2"],"sponsor":"University of Wisconsin, Madison","primaryCompletion":"2026-08-31","kind":"status","from":"RECRUITING","to":"COMPLETED"},{"detected":"2026-10-05","drugId":"pylarify","nct":"NCT04573231","title":"Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer","phases":["PHASE2"],"sponsor":"University of Wisconsin, Madison","primaryCompletion":"2026-08-31","kind":"primary-completion","from":"2026-08","to":"2026-08-31"},{"detected":"2026-10-05","drugId":"enzalutamide","nct":"NCT05081193","title":"Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer","phases":["PHASE2"],"sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","primaryCompletion":"2025-08-04","kind":"status","from":"COMPLETED","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"enzalutamide","nct":"NCT05081193","title":"Safety and Efficacy of Oral Testosterone Undecanoate Followed by Enzalutamide as Therapy for Men With Metastatic Castrate Resistant Prostate Cancer","phases":["PHASE2"],"sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","primaryCompletion":"2025-08-04","kind":"results-posted"},{"detected":"2026-10-05","drugId":"ga68-psma-11","nct":"NCT05176223","title":"68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2025-12-31","kind":"results-posted"},{"detected":"2026-10-05","drugId":"ryz101","nct":"NCT05477576","title":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","phases":["PHASE3"],"sponsor":"RayzeBio, Inc.","primaryCompletion":"2026-12","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-10-05","drugId":"tlx-591","nct":"NCT06549465","title":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","phases":["PHASE2"],"sponsor":"Convergent Therapeutics","primaryCompletion":"2027-08","kind":"primary-completion","from":"2027-04-20","to":"2027-08"},{"detected":"2026-10-05","drugId":"ga-68-fapi-46","nct":"NCT06604260","title":"FAPi-PET Imaging of in Vivo Fibrosis in Inflammatory Bowel Disease Patients","phases":["PHASE2"],"sponsor":"Dalia Lartey","primaryCompletion":"2024-12-31","kind":"status","from":"RECRUITING","to":"UNKNOWN"},{"detected":"2026-10-05","drugId":"cabazitaxel","nct":"NCT06738303","title":"Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer","phases":["PHASE2"],"sponsor":"Case Comprehensive Cancer Center","primaryCompletion":"2028-02-20","kind":"primary-completion","from":"2026-12","to":"2028-02-20"},{"detected":"2026-10-05","drugId":"enzalutamide","nct":"NCT07802704","title":"A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]","phases":["PHASE3"],"sponsor":"GlaxoSmithKline","primaryCompletion":"2029-12-05","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-10-05","drugId":"enzalutamide","nct":"NCT07802704","title":"A Study of Risvutatug Rezetecan in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) [EMBOLD Prostate-302]","phases":["PHASE3"],"sponsor":"GlaxoSmithKline","primaryCompletion":"2029-12-05","kind":"primary-completion","from":"2029-12-19","to":"2029-12-05"},{"detected":"2026-10-05","drugId":"pluvicto","nct":"NCT07852195","title":"Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer","phases":["PHASE2","PHASE3"],"sponsor":"ECOG-ACRIN Cancer Research Group","primaryCompletion":"2029-03-31","kind":"new-study","to":"NOT_YET_RECRUITING"},{"detected":"2026-09-28","drugId":"abiraterone","nct":"NCT03568656","title":"Study to Evaluate CCS1477 in Advanced Tumours","phases":["PHASE1","PHASE2"],"sponsor":"CellCentric Ltd.","primaryCompletion":"2025-07-06","kind":"results-posted"},{"detected":"2026-09-28","drugId":"abiraterone","nct":"NCT06369610","title":"Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2028-07-29","kind":"status","from":"RECRUITING","to":"ACTIVE_NOT_RECRUITING"},{"detected":"2026-09-28","drugId":"abiraterone","nct":"NCT06369610","title":"Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2028-07-29","kind":"primary-completion","from":"2027-04-22","to":"2028-07-29"},{"detected":"2026-09-28","drugId":"flotufolastat","nct":"NCT07025369","title":"Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial","phases":["PHASE2"],"sponsor":"Mayo Clinic","primaryCompletion":"2029-01-01","kind":"primary-completion","from":"2026-12-31","to":"2029-01-01"},{"detected":"2026-09-28","drugId":"pylarify","nct":"NCT07686380","title":"IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapy","phases":["PHASE2"],"sponsor":"National Cancer Institute (NCI)","primaryCompletion":"2029-01-30","kind":"status","from":"NOT_YET_RECRUITING","to":"RECRUITING"},{"detected":"2026-09-28","drugId":"tc-99m-pyrophosphate","nct":"NCT07835880","title":"[18F]FIDT-10b PET Imaging in Cardiac Amyloidosis","phases":["PHASE1","PHASE2"],"sponsor":"Peking Union Medical College Hospital","primaryCompletion":"2027-12-31","kind":"new-study","to":"NOT_YET_RECRUITING"}]}